INTEGRATED FILING — Other than Banks



General information about company

Scrip code 544067
NSE Symbol INNOVACAP
MSEI Symbol NOTLISTED
ISIN INE0DUT01020
Name of Company INNOVA CAPTAB LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 12-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Drugs and Pharmaceutical products
Start date and time of board meeting 19-May-2025   15:38:00
End date and time of board meeting 19-May-2025   17:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-05
Indicate Company website link for updated RPT policy of the Company https://www.innovacaptab.com/corporate-governance.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes


Financial Results — Other than Bank
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 2425220000 9580610000
Other income 43560000 167750000
Total Income 2468780000 9748360000
2 Expenses
(a) Cost of materials consumed 1874180000 7155100000
(b) Purchases of stock-in-trade 2340000 6840000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -136070000 -113420000
(d) Employee benefit expense 213210000 627430000
(e) Finance costs 18690000 21680000
(f) Depreciation and amortisation expense
(g) Other Expenses
1 Power and fuel 54210000 150690000
2 Packing charges 28200000 94940000
3 Stores and spares consumed 21120000 72440000
4 Repairs and maintenance 15480000 54680000
5 Miscellaneous expenses 17780000 151610000
6 Lab consumables 7830000 37090000
7 Bad debts written off 14400000 32850000
8 Rates, fees and taxes 9350000 31410000
9 House keeping expense 11550000 30010000
10 Travelling and conveyance 9840000 25950000
Total other expenses 189760000 681670000
Total expenses 2240230000 8549450000
3 Profit before exceptional and extraordinary items and tax
4 Exceptional items
5 Profit before extraordinary items and tax
6 Extraordinary items
7 Profit before tax 228550000 1198910000
8 Tax Expense
Current tax 27410000 220000000
Deferred tax 29890000 84210000
Total tax expenses 57300000 304210000
9 Net Profit Loss for the period from continuing operations
10 Profit (loss) from discontinuing operations before tax
11 Tax expense of discontinuing operations
12 Net profit (loss) from discontinuing operation after tax
13 Profit (loss) for period before minority interest
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period
17 Details of equity share capital
Paid-up equity share capital 572250000 572250000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 7557400000
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.99 15.63
Diluted earnings (loss) per share from continuing and discontinued operations 2.99 15.63
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio
23 Disclosure of notes on financial results Textual Information(1)


Text Block
Textual Information(1) The above standalone financial results of Innova Captab Limited ( the Company ) have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ( the act ) read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. The results for the quarter and year ended 31 March 2025 are available on the Company's website i.e. www.innovacaptab.com under investor information section and on the stock exchange website i.e. www.bseindia.com and www.nseindia.com. The above standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 19 May 2025. The Board of Directors at their meeting held on 19 May 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the quarter and year ended 31 March 2025. 'The Company has only one reportable segment i.e. “Drugs and pharmaceutical products” as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. Accordingly , the disclosures as per the listing agreement are not applicable to the group. 'The figures of the last quarter of the year ended 31 March 2025 and the corresponding quarter ended in the previous year, as reported in these annual financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit.


Remarks
20 Debt equity ratio
21 Debt service coverage ratio Earning available for Debt Service is 1084.53 mn. however, total interest and principal repayments are 440.79 mn.
22 Interest service coverage ratio EBIDTA is 8.5 times of Interest paid and such increase in EBIDTA is due to generl increase in operations.


Cash flow statement — indirect
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 0
Adjustments for depreciation and amortisation expense 170150000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 3850000
Adjustments for unrealised foreign exchange losses gains 4340000
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow 800000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 71050000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss)
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories -459050000
Adjustments for decrease (increase) in trade receivables
Adjustments for decrease (increase) in other current assets -73980000
Adjustments for increase (decrease) in trade payables
Adjustments for increase (decrease) in other current liabilities -8840000
Adjustments for provisions
Total adjustments for working capital
Total adjustments for reconcile profit (loss) -689710000
Net cash flows from (used in) operations 509200000
Dividends received 0
Interest paid -21680000
Interest received -138920000
Income taxes paid (refund) 193950000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities before extraordinary items
Proceeds from extraordinary items
Payment for extraordinary items
Net cash flows from (used in) operating activities 198010000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 1480000
Purchase of property plant and equipment 1609290000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 295000000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 147790000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 167560000
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items
Proceeds from extraordinary items
Payment for extraordinary items
Net cash flows from (used in) investing activities -997460000
Cash flows from used in financing activities
Proceeds from issuing shares
Proceeds from issuing other equity instruments 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 976150000
Repayments of borrowings 114030000
Dividends paid 0
Interest paid 15940000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities before extraordinary items
Proceeds from extraordinary items
Payment for extraordinary items
Net cash flows from (used in) financing activities 838630000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 39180000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 39180000
Cash and cash equivalents cash flow statement at beginning of period 113890000
Cash and cash equivalents cash flow statement at end of period 153070000


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital
Reserves and surplus
Money received against share warrants
Total shareholders' funds
2 Share application money pending allotment
3 Deferred government grants
4 Minority interest
5 Non-current liabilities
Long-term borrowings
Deferred tax liabilities (net) 131870000
Foreign currency monetary item translation difference liability account
Other long-term liabilities
Long-term provisions
Total non-current liabilities 2620150000
6 Current liabilities
Short-term borrowings
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other current liabilities 26730000
Short-term provisions
Total current liabilities 2901640000
Total equity and liabilities 13651440000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 6369110000
Producing properties
Intangible assets
Preproducing properties
Property, Plant and Equipment capital work-in-progress
Intangible assets under development or work-in-progress
Total Property, Plant and Equipment and Intangible assets
ii Non-current investments 600000000
v Deferred tax assets (net) 0
vi Foreign currency monetary item translation difference asset account
vii Long-term loans and advances
viii Other non-current assets 32320000
Total non-current assets 8360360000
Current assets
Current investments 0
Inventories 1399450000
Trade receivables
Cash and cash equivalents 153070000
Bank balance other than cash and cash equivalents 525850000
Short-term loans and advances
Other current assets 403540000
Total current assets 5291080000
Total assets 13651440000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments Textual Information(1)


Text Block
Textual Information(1) The Company's operations relate to only one reportable segment viz Drugs and Pharmaceuticals. Accordingly, no separate disclosure of segment information is required.




Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s B S R & Co., LLP Yes 31-Jul-2025


Financial details
Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth


Signatories details

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-Dec-2023
Amount Raised 5700000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment and/or prepayment, in part or in full, of certain outstanding loansof the company Not Applicable 1444000000 0 1444000000 0
2 Investment in the subsidiary, UML, for repayments and/or prepayment n part or full of outstandng loans availed by UML Not Applicable 236000000 0 236000000 0
3 funding working capital requirements of the company Not Applicable 720000000 0 720000000 0
4 general corporate purposes Not Applicable 531090000 0 531090000 0 the amount of original alllocation represents the amount raised through Fresh Issue (net of offer expenses as mentioned in the prospectus dated december 26, 2023


Signatory Details
Name of signatory Neeharika Shukla
Designation of person Company Secretary and Compliance Officer
Place Chandigarh
Date 19-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Innova Captab Limited Nugenic Pharma Private Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and shareholder in Nugenic Pharma Private Limited Purchase of goods or services 900000000 Approved by Audit Committee 328430000 186990000 175660000
2 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Purchase of goods or services Approved by Audit Committee 1890000 0 0
3 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Sale of goods or services Approved by Audit Committee 816260000 416300000 489340000
4 Innova Captab Limited Shubh Packaging Ms. Vandana Gohlyan (Sister of Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala,) is a partner in Shubh Packaging Purchase of goods or services 300000000 Approved by Audit Committee 56720000 15660000 12320000
5 Innova Captab Limited Pharmatech Healthcare Mr. Shyamsundar Aggarwal (Brother of Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala) is a director in Pharmatech Healthcare Sale of goods or services 50000000 Approved by Audit Committee 8270000 18260000 20770000
6 Innova Captab Limited Azine Healthcare Private Limited Mr. Shyamsundar Aggarwal (Brother of Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala) is a director in Azine Healthcare Private Limited Sale of goods or services 30000000 Approved by Audit Committee 660000 5130000 4140000
7 Innova Captab Limited Sharon Bio Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Purchase of goods or services Approval is not required as step down subsidiary of the Company 3820000 190000 0
8 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Inter-corporate deposit Approved by Board of Directors 245000000 1316000000 1071000000
9 Innova Captab Limited Vinay Kumar Lohariwala Managing Director Remuneration Approved by Board of Directors 5540000 620000 610000
10 Innova Captab Limited Manoj Kumar Lohariwala Whole Time Director Remuneration Approved by Board of Directors 5540000 620000 610000
11 Innova Captab Limited Neeharika Shukla Company Secretary & Compliance Officer Remuneration Approved by Board of Directors 550000 80000 70000
12 Innova Captab Limited Mukeshkumar Siyaram Singh Key Managerial Personnel Remuneration Approved by Board of Directors 1690000 190000 180000
13 Innova Captab Limited Jayant Vasudeo Rao Whole Time Director Remuneration Approved by Board of Directors 910000 130000 130000
14 Innova Captab Limited LOKESH BHASIN Chief Financial Officer Remuneration Approved by Board of Directors 3510000 390000 380000
15 Innova Captab Limited Sharon Bio Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Any other transaction Rental Income Approval is not required as step down subsidiary of the Company 2030000 0 400000
16 Innova Captab Limited Sharon Bio Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Any other transaction Electricity Reimbursement Approval is not required as step down subsidiary of the Company 330000 0 60000
17 Innova Captab Limited Sharon Bio Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Sale of goods or services Approval is not required as step down subsidiary of the Company 0 0 0
18 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Interest received Loan approved by Board of Direcors 53170000 8270000 0
19 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Any other transaction Rental Income Rent approved by Board of Direcors 1320000 360000 0
20 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Kumar Lohariwala, Directors of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Any other transaction Insurance Reimbursement approved by Board of Direcors 500000 0 0
21 Innova Captab Limited Sudhir Kumar Bassi Independent Director Any other transaction Sitting Fee Approved by Board of Directors 350000 0 0
22 Innova Captab Limited Priyanka Sibal Independent Director Any other transaction Sitting Fee Approved by Board of Directors 190000 0 0
23 Innova Captab Limited Shirish Gundopant Belapure Independent Director Any other transaction Sitting Fee Approved by Board of Directors 190000 0 0
24 Innova Captab Limited Mahendar Korthiwada Independent Director Any other transaction Sitting Fee Approved by Board of Directors 270000 0 0
25 Innova Captab Limited Mukeshkumar Siyaram Singh Key Managerial Personnel Any other transaction Loan repaid NA 150000 950000 800000
26 Innova Captab Limited ANSHIKA LOHARIWALA Daughter of Chairman Remuneration Approved by Audt Committee & Board of Direcors 1210000 0 200000
Total value of transaction during the reporting period 1538500000





Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 0